Sökning: id:"swepub:oai:DiVA.org:oru-56853" >
Changes of cerebros...
Changes of cerebrospinal fluid cytokine profile as a result of switching from first line MS-therapies to rituximab
-
- de Flon, P. (författare)
- Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden
-
- Söderström, L. (författare)
- Unit of Research, Education and Development, Region Jämtland Härjedalen, Östersund, Sweden
-
- Laurell, K. (författare)
- Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden
-
visa fler...
-
- Gunnarsson, Martin, 1973- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Neurology and Neurophysiology, Örebro University Hospital, Örebro, Sweden
-
- Svenningsson, A. (författare)
- Department of Clinical Sciences, Karolinska Institute, Stockholm, Sweden
-
visa färre...
-
(creator_code:org_t)
- Sage Publications, 2016
- 2016
- Engelska.
-
Ingår i: Multiple Sclerosis Journal. - : Sage Publications. - 1352-4585 .- 1477-0970. ; 22:Suppl. 3, s. 622-622
- Relaterad länk:
-
https://urn.kb.se/re...
Abstract
Ämnesord
Stäng
- Background: New treatment strategies in multiple sclerosis provide insights not only in the clinical effects but also, by their differences in mechanisms of action, in the immunopathological mechanisms behind disease activity.Objective: This study describes the change in cyto- and chemokine profile over a two-year period in a cohort of patients with clinically stable RRMS after treatment shift from ongoing first-line injectable disease modifying therapy (iDMT), e.g. interferon beta or glatirameracetat, to the anti-CD20 depleting agent rituximab and the differences compared with a cohort of healthy controls.Method: CSF from 73 patients with clinically stable RRMS was analysed by an elektrochemiluminiscens-based ELISA for a panel of 22 cytokines before and one and two year after treatment shift to rituximab and compared with 55 healthy controls.Results: During the first year of treatment it was a significant reduction (p< 0.005) in levels of IL-6, IL-8, IL-10, IL-12, IL-15, IP-10, MCP-1, MDC, TARC, sICAM, sVCAM and a significant elevation (p< 0,005) in levels of IL-7 and MIP-1b.Compared to healthy controls it was a significantly higher (p< 0,005) level of IFN-gamma, IL-6, IL-8, IL-10, IL-12, IL-15, TNF, IP-10, MDC, MIP-1a, MIP-1b, TARC, SAA, sICAM and sVCAM in patients with RRMS before treatment shift. Levels of IL-5 and IL-7 were significantly lower. One year after treatment shift the levels of IFN-gamma, IL-6, IL-7, IL-15, MIP-1a and SAA did not differ significantly between patients with RRMS and healthy controls.Conclusion: This study demonstrates significant changes in cyto- and chemokine profile in patients with RRMS after treatment shift from iDMT to rituximab and compared with healthy controls.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas